Diane Weiser
Senior Vice President of Corporate Affairs
Replay available
Cytokinetics, Incorporated (NASDAQ: CYTK) Q4 2025 earnings conference call, held 2026-02-24. Replay captured from the company's public earnings webcast.

Senior Vice President of Corporate Affairs
President and Chief Executive Officer
Executive Vice President and Chief Commercial Officer
Executive Vice President of Research and Development
Senior Vice President and Chief Medical Officer
Executive Vice President and Chief Financial Officer
Watch the replay and follow the connected company analysis, news, and investor updates for Cytokinetics, Incorporated.
WEBVTT 00:00:01.060 -- 00:00:06.927 Thank you for standing by and welcome to the cytokinetics fourth quarter 2025 00:00:06.927 -- 00:00:12.114 earnings call. This call is being recorded and all participants are in a listen only 00:00:12.114 -- 00:00:17.100 mode. After the speaker's remarks, we will open the call to questions. 00:00:17.100 -- 00:00:20.965 We will allow for one question per participant. 00:00:20.965 -- 00:00:25.150 If you would like to ask a question during this time, simply press star followed by the 00:00:25.150 -- 00:00:29.996 number one on your telephone keypad. And if you'd like to withdraw your question, press 00:00:29.996 -- 00:00:35.413 star one again. I would now like to turn the call over to Diane Weiser, 00:00:35.413 -- 00:00:39.559 CytoKinetics Senior Vice President of Corporate Affairs. 00:00:39.559 -- 00:00:42.140 Please go ahead. 00:00:42.223 -- 00:00:44.887 Good afternoon, and thanks for joining us on the call today. 00:00:44.887 -- 00:00:49.354 Robert Blum, President and Chief Executive Officer, will begin with an overview of the 00:00:49.354 -- 00:00:54.782 quarter and recent developments. Andrew Kalos, EVP and Chief Commercial Officer, 00:00:54.782 -- 00:00:57.686 will discuss the commercial launch of MyCorso in the U.S. 00:00:57.686 -- 00:01:02.957 and readiness in Europe. Patty Malek, EVP of R&D, and Stuart Kupfer, SVP 00:01:02.957 -- 00:01:08.563 and Chief Medical Officer, will provide updates related to our clinical development programs. 00:01:08.563 -- 00:01:13.568 Sung Lee, EVP and Chief Financial Officer, will provide a financial overview of 2025 00:01:13.568 -- 00:01:18.814 and discuss our 2026 financial guidance. And finally, Robert will then make closing 00:01:18.814 -- 00:01:22.438 remarks and review key milestones for the...